These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31195900)

  • 1. Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.
    Wijnen BFM; Thielen FW; Konings S; Feenstra T; Van Der Gaag M; Veling W; De Haan L; Ising H; Hiligsmann M; Evers SMAA; Smit F; Lokkerbol J
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):269-279. PubMed ID: 31195900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.
    Ising HK; Lokkerbol J; Rietdijk J; Dragt S; Klaassen RM; Kraan T; Boonstra N; Nieman DH; van den Berg DP; Linszen DH; Wunderink L; Veling W; Smit F; van der Gaag M
    Schizophr Bull; 2017 Mar; 43(2):365-374. PubMed ID: 27306315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2018; 18(5):1-141. PubMed ID: 30443277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder.
    Lokkerbol J; Wijnen B; Ruhe HG; Spijker J; Morad A; Schoevers R; de Boer MK; Cuijpers P; Smit F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1031-1042. PubMed ID: 33119427
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
    Ologundudu OM; Palaniyappan L; Cipriano LE; Wijnen BFM; Anderson KK; Ali S
    Schizophr Res; 2023 Nov; 261():225-233. PubMed ID: 37804598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial.
    Ising HK; Smit F; Veling W; Rietdijk J; Dragt S; Klaassen RM; Savelsberg NS; Boonstra N; Nieman DH; Linszen DH; Wunderink L; van der Gaag M
    Psychol Med; 2015 May; 45(7):1435-46. PubMed ID: 25330734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States.
    Ross EL; Becker JE; Linnoila JJ; Soeteman DI
    J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33211912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.
    Ising HK; Kraan TC; Rietdijk J; Dragt S; Klaassen RM; Boonstra N; Nieman DH; Willebrands-Mendrik M; van den Berg DP; Linszen DH; Wunderink L; Veling W; Smit F; van der Gaag M
    Schizophr Bull; 2016 Sep; 42(5):1243-52. PubMed ID: 26994397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying economic models to estimate local economic benefits of improved coverage of early intervention for psychosis.
    Campion J; Taylor MJ; McDaid D; Park AL; Shiers D
    Early Interv Psychiatry; 2019 Dec; 13(6):1424-1430. PubMed ID: 30740880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial.
    Reininghaus U; Klippel A; Steinhart H; Vaessen T; van Nierop M; Viechtbauer W; Batink T; Kasanova Z; van Aubel E; van Winkel R; Marcelis M; van Amelsvoort T; van der Gaag M; de Haan L; Myin-Germeys I
    Trials; 2019 Dec; 20(1):769. PubMed ID: 31878966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary cortisol in early psychosis: New findings and meta-analysis.
    Chaumette B; Kebir O; Mam-Lam-Fook C; Morvan Y; Bourgin J; Godsil BP; Plaze M; Gaillard R; Jay TM; Krebs MO
    Psychoneuroendocrinology; 2016 Jan; 63():262-70. PubMed ID: 26520686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Extended Early Intervention Service vs Regular Care Following 2 Years of Early Intervention: Secondary Analysis of a Randomized Controlled Trial.
    Groff M; Latimer E; Joober R; Iyer SN; Schmitz N; Abadi S; Abdel-Baki A; Casacalenda N; Margolese HC; Jarvis GE; Malla A
    Schizophr Bull; 2021 Mar; 47(2):465-473. PubMed ID: 32918474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Virtual Reality Cognitive Behavioral Therapy for Psychosis: Health-Economic Evaluation Within a Randomized Controlled Trial.
    Pot-Kolder R; Veling W; Geraets C; Lokkerbol J; Smit F; Jongeneel A; Ising H; van der Gaag M
    J Med Internet Res; 2020 May; 22(5):e17098. PubMed ID: 32369036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis.
    Barton GR; Hodgekins J; Mugford M; Jones PB; Croudace T; Fowler D
    Schizophr Res; 2009 Jul; 112(1-3):158-63. PubMed ID: 19403270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
    Verbeek JGE; Atema V; Mewes JC; van Leeuwen M; Oldenburg HSA; van Beurden M; Hunter MS; van Harten WH; Aaronson NK; Retèl VP
    Breast Cancer Res Treat; 2019 Dec; 178(3):573-585. PubMed ID: 31451978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial.
    van der Gaag M; Nieman DH; Rietdijk J; Dragt S; Ising HK; Klaassen RM; Koeter M; Cuijpers P; Wunderink L; Linszen DH
    Schizophr Bull; 2012 Nov; 38(6):1180-8. PubMed ID: 22941746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for people at ultra-high risk for psychosis: A systematic review of economic evaluations.
    Ologundudu OM; Lau T; Palaniyappan L; Ali S; Anderson KK
    Early Interv Psychiatry; 2021 Oct; 15(5):1115-1126. PubMed ID: 33047497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector.
    Murphy SM; Kucukgoncu S; Bao Y; Li F; Tek C; Breitborde NJK; Guloksuz S; Phutane VH; Ozkan B; Pollard JM; Cahill JD; Woods SW; Cole RA; Schoenbaum M; Srihari VH
    J Ment Health Policy Econ; 2018 Sep; 21(3):123-130. PubMed ID: 30530872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.